Clinical Trial Update: Panhematin for Prevention of Acute Attacks of Porphyria [Phase 2]

View source ↗

Summary

Phase 2 study of Panhematin (hemin) to prevent acute attacks in porphyrias was terminated, with results posted on 2026-01-30.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Coproporphyria
• Intermittent Porphyria
• Variegate Porphyria

Drugs mentioned

• Panhematin (heme arginate (hemin))

Snippet

Sponsor: The University of Texas Medical Branch, Galveston | Conditions: Acute Intermittent Porphyria, Hereditary Coproporphyria | Phase 2 | Status: TERMINATED | Results posted: 2026-01-30